Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz maintains a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $38 to $64.
June 18, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst David Lebowitz maintains a Buy rating on Mirum Pharmaceuticals and raises the price target from $38 to $64.
The raised price target from $38 to $64 by a reputable analyst at Citigroup is a strong positive signal for investors, indicating confidence in Mirum Pharmaceuticals' future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100